Vaxcyte/$PCVX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Vaxcyte

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

Ticker

$PCVX
Sector
Primary listing

Employees

414

Vaxcyte Metrics

BasicAdvanced
$5.5B
-
-$4.13
1.21
-

What the Analysts think about Vaxcyte

Analyst ratings (Buy, Hold, Sell) for Vaxcyte stock.

Bulls say / Bears say

As of June 30, 2025, Vaxcyte held approximately $2.83 billion in cash, cash equivalents, and investments, extending its funding runway to mid-2028 due to disciplined capital allocation.
After an FDA End-of-Phase 2 meeting and under its Breakthrough Therapy designation, Vaxcyte has finalized the VAX-31 Phase 3 adult program, selecting a high-dose regimen for a pivotal non-inferiority study starting in Q4 2025. This positions it as a potential new standard of care.
The modified VAX-31 infant Phase 2 randomized, dose-finding study has progressed to the third and final stage, now enrolling with the optimized dose arm. The company aims to deliver topline immunogenicity and booster data by mid-2027, with the potential to cover about 92% of invasive pneumococcal disease in U.S. children under five.
Net loss for Q2 2025 widened to $166.6 million from $128.7 million a year earlier, with R&D expenses rising to $194.2 million and G&A to $32.0 million, highlighting increased cash burn and execution risk ahead of pivotal Phase 3 data.
Vaxcyte halted development beyond preclinical stages for VAX-A1 (Group A Strep) and VAX-GI (Shigella), and discontinued VAX-PG (periodontal disease), narrowing its pipeline and making it increasingly reliant on the success of its PCV franchise.
Capital and facility buildout costs for the Lonza manufacturing suite reached $290.6 million as of June 30, 2025, with total completion projected at $300–350 million by early 2026. This poses potential pressure on liquidity and may divert resources from R&D.
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

Vaxcyte Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Vaxcyte Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PCVX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs